NasdaqGS:COGTBiotechs
Cogent Biosciences (COGT) Stock Can APEX Trial Progress Justify A 10.6x P B Ratio
Cogent Biosciences (COGT) stock is in focus after the company released updated APEX trial data for bezuclastinib in advanced systemic mastocytosis, along with preclinical results for JAK2 V617F inhibitor CGT1145 at the 2026 EHA Congress.
See our latest analysis for Cogent Biosciences.
The latest APEX and CGT1145 data arrive as Cogent Biosciences trades at US$33.67, with recent momentum reflected in a 7.3% 7 day share price return. The 1 year total shareholder return of about 4.7x highlights...